The Precision Peptide Company Inc. (CSE: BPC) (OTCQB: PNGAF) announced plans to raise between $1.5 million and $2 million through a private placement of common shares. The Vancouver-based wellness company intends to issue between 3 million and 4 million shares at $0.50 per share.

The offering will be conducted under Canada's listed issuer financing exemption and is available to residents of all Canadian provinces except Quebec. Shares issued under this exemption will not be subject to a hold period under Canadian securities laws.

The company stated it will use net proceeds for general working capital, advancing business objectives, funding marketing initiatives, and supporting inventory and product procurement. The offering is expected to close on or around June 25, 2026, and may occur in multiple tranches.

Completion of the offering remains subject to certain conditions, including receipt of necessary approvals. The company may pay finder's fees to eligible parties in connection with the offering, in accordance with Canadian Securities Exchange policies.

The Precision Peptide Company describes itself as a publicly traded wellness company focused on peptide formulations and delivery systems. The company manufactures products in a U.S. facility and distributes across North America.

The securities have not been registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States without registration or an applicable exemption.